This is the classic website, which will be retired eventually. Please visit the modernized instead.

Key Record Dates Identifier: NCT05091567
Brief Title: A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte)

First Submitted : October 12, 2021
First Submitted that Met QC Criteria : October 12, 2021
First Posted : October 25, 2021

Last Update Submitted that Met QC Criteria : March 10, 2024
Last Update Posted : March 12, 2024